J. Goldman & Co LP Takes $1.14 Million Position in Rezolute, Inc. (NASDAQ:RZLT)

J. Goldman & Co LP bought a new stake in Rezolute, Inc. (NASDAQ:RZLT) in the 4th quarter, according to its most recent filing with the SEC. The fund bought 232,627 shares of the company’s stock, valued at approximately $1,140,000. J. Goldman & Co LP owned 0.40% of Rezolute at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. JPMorgan Chase & Co. acquired a new position in Rezolute during the third quarter worth $42,000. Charles Schwab Investment Management Inc. raised its position in shares of Rezolute by 65.4% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 22,757 shares of the company’s stock valued at $112,000 after buying an additional 9,000 shares during the last quarter. Alpine Global Management LLC acquired a new stake in shares of Rezolute in the fourth quarter valued at about $54,000. Jacobs Levy Equity Management Inc. raised its position in shares of Rezolute by 41.9% in the fourth quarter. Jacobs Levy Equity Management Inc. now owns 69,989 shares of the company’s stock valued at $343,000 after buying an additional 20,667 shares during the last quarter. Finally, American Century Companies Inc. raised its position in shares of Rezolute by 62.1% in the fourth quarter. American Century Companies Inc. now owns 64,591 shares of the company’s stock valued at $316,000 after buying an additional 24,742 shares during the last quarter. 82.97% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Rezolute news, CEO Nevan C. Elam bought 12,302 shares of the stock in a transaction dated Thursday, March 27th. The shares were acquired at an average cost of $2.85 per share, for a total transaction of $35,060.70. Following the completion of the transaction, the chief executive officer now owns 224,119 shares in the company, valued at approximately $638,739.15. The trade was a 5.81% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Wladimir Hogenhuis bought 10,000 shares of the stock in a transaction dated Tuesday, February 18th. The shares were acquired at an average price of $4.70 per share, for a total transaction of $47,000.00. Following the completion of the transaction, the director now owns 77,267 shares of the company’s stock, valued at approximately $363,154.90. The trade was a 14.87% increase in their position. The disclosure for this purchase can be found here. Over the last quarter, insiders have purchased 39,060 shares of company stock valued at $130,694. 18.39% of the stock is owned by corporate insiders.

Rezolute Stock Down 0.8%

Shares of NASDAQ:RZLT opened at $3.69 on Monday. The firm’s 50 day moving average price is $3.25 and its 200 day moving average price is $4.36. The stock has a market cap of $223.37 million, a price-to-earnings ratio of -3.02 and a beta of 1.01. Rezolute, Inc. has a fifty-two week low of $2.22 and a fifty-two week high of $6.19.

Rezolute (NASDAQ:RZLT) last released its quarterly earnings data on Wednesday, February 12th. The company reported ($0.22) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.11. On average, equities analysts anticipate that Rezolute, Inc. will post -0.93 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on RZLT shares. Guggenheim reissued a “buy” rating on shares of Rezolute in a report on Monday, February 10th. HC Wainwright reissued a “buy” rating and issued a $14.00 price objective on shares of Rezolute in a research note on Monday, April 28th. JMP Securities raised their price objective on shares of Rezolute from $8.00 to $9.00 and gave the company a “market outperform” rating in a research note on Thursday, February 13th. Finally, Craig Hallum raised shares of Rezolute to a “strong-buy” rating in a research note on Tuesday, February 4th. Six research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $26.43.

Rezolute Company Profile

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.